Inhibiting the Mammalian Target of Rapamycin Blocks the Development of Experimental Cerebral Malaria

Emile B. Gordon,** Geoffrey T. Hart,a Tuan M. Tran,a Michael Waisberg,** Munir Akkaya,a Jeff Skinner,a Severin Zinöcker,** Mirna Pena,a Takele Yazew,a Chen-Feng Qi,a Louis H. Miller,b Susan K. Piercea

Laboratory of Immunogeneticsa and Laboratory of Malaria and Vector Research;b National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA

* Present address: Emile B. Gordon, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Michael Waisberg, Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Severin Zinöcker, AbbVie Norway, Fornebu, Norway.

© 2015 Gordon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

A B S T R A C T  Malaria is an infectious disease caused by parasites of several *Plasmodium* spp. Cerebral malaria (CM) is a common form of severe malaria resulting in nearly 700,000 deaths each year in Africa alone. At present, there is no adjunctive therapy for CM. Although the mechanisms underlying the pathogenesis of CM are incompletely understood, it is likely that both intrinsic features of the parasite and the human host’s immune response contribute to disease. The kinase mammalian target of rapamycin (mTOR) is a central regulator of immune responses, and drugs that inhibit the mTOR pathway have been shown to be antiparasitic. In a mouse model of CM, experimental CM (ECM), we show that the mTOR inhibitor rapamycin protects against ECM when administered within the first 4 days of infection. Treatment with rapamycin increased survival, blocked breakdown of the blood-brain barrier and brain hemorrhaging, decreased the influx of both CD4+ and CD8+ T cells into the brain and the accumulation of parasitized red blood cells in the brain. Rapamycin induced marked transcriptional changes in the brains of infected mice, and analysis of transcription profiles predicted that rapamycin blocked leukocyte trafficking to and proliferation in the brain. Remarkably, animals were protected against ECM even though rapamycin treatment significantly increased the inflammatory response induced by infection in both the brain and spleen. These results open a new avenue for the development of highly selective adjunctive therapies for CM by targeting pathways that regulate host and parasite metabolism.

I M P O R T A N C E  Malaria is a highly prevalent infectious disease caused by parasites of several *Plasmodium* spp. Malaria is usually uncomplicated and resolves with time; however, in about 1% of cases, almost exclusively among young children, malaria becomes severe and life threatening, resulting in nearly 700,000 deaths each year in Africa alone. Among the most severe complications of *Plasmodium falciparum* infection is cerebral malaria with a fatality rate of 15 to 20%, despite treatment with antimalarial drugs. Cerebral malaria takes a second toll on African children, leaving survivors at high risk of debilitating neurological defects. At present, we have no effective adjunctive therapies for cerebral malaria, and developing such therapies would have a large impact on saving young lives in Africa. Here we report results that open a new avenue for the development of highly selective adjunctive therapies for cerebral malaria by targeting pathways that regulate host and parasite metabolism.

Malaria is a highly prevalent infectious disease caused by parasites of several *Plasmodium* spp., the most deadly of which, *Plasmodium falciparum*, prevails in Africa. In individuals living in areas where malaria is endemic, it is usually uncomplicated and resolves with time even in the absence of treatment with antimalarial drugs. However, in about 1% of cases, almost exclusively among young children, malaria becomes severe and life threatening, resulting in nearly 700,000 deaths each year in Africa alone (1). Among the most severe complications of *P. falciparum* infection in humans is human cerebral malaria (HCM) with a case fatality rate of 15 to 20% in African children despite effective antimalarial chemotherapy (2, 3). HCM takes a second toll on African children, leaving survivors at high risk of debilitating neurological defects (4). At present, we have no effective adjunctive therapies for HCM, and developing such therapies in combination with antimalarial drugs would have a large impact on improving global public health.

Currently, our understanding of the pathogenesis of HCM is far from complete and relies heavily on the analysis of histopathology of brain tissue from children who died from HCM (5, 6). Although HCM is a clinically heterogeneous disease, the commonly accepted definition of HCM centers around neurological
symptoms, ultimately unarousable coma, with the presence of infected red blood cells (iRBCs) in the peripheral circulation system with no other apparent causes of coma (7). Recently, the correct diagnosis of HCM was greatly improved by the use of retinal exams to identify histological features of HCM, correcting what was estimated to be 25 to 30% misdiagnosed cases (8). Sequestration of iRBCs on the brain vascular endothelium is a defining feature of HCM (5). Other common features of the brain histopathology in clinically well-characterized HCM patients include brain microhemorrhages associated with axonal and myelin damage, disruption of the blood-brain barrier (BBB), and brain swelling (5, 6). Systemic activation of the endothelium has also been reported in HCM patients and appears to correlate with disease severity (9). HCM is also characterized by the production of high levels of proinflammatory cytokines and chemokines that have been correlated with HCM pathogenesis (10, 11). The accumulation of both monocytes with phagocytosed hemozoin (5) and platelets (12), as well as a small number of intravascular leukocytes, including CD8+ T cells, has also been observed in brain sections of HCM patients (5, 12). As both the host immune response and sequestration of iRBCs appear to contribute to the pathogenesis of HCM, successful therapies may be ones that target both the host immune response and the parasite.

The mouse model of CM, experimental CM (ECM), recapitulates many characteristics of HCM and therefore may be a useful tool to identify candidates for adjunctive therapy in the human disease (13, 14). Infection of susceptible C57BL/6 mice with Plasmodium berghei ANKA (PbA) parasites results in death of up to 100% of mice usually within 6 to 14 days postinfection (p.i.) following clear signs of neurological damage, including paralysis, ataxia, convulsions, and coma (13). Strains of mice resistant to PbA-induced ECM do not show clinical signs of neurological damage but die 2 to 3 weeks after infection due to anemia caused by hyperparasitemia (13). Examination of the brains of mice with late-stage ECM show many of the features common to HCM, including accumulation of iRBCs along venular endothelium, microhemorrhages, breakdown of the BBB, and brain swelling (7, 13). Although the degree of sequestration of iRBCs in the brains in ECM appears in general to be less than that in HCM (14), the presence of iRBCs in the brains of infected mice has been shown to be necessary for the development of ECM (15–17). ECM is also associated with a marked accumulation of various immune cells in the brains of infected animals, including T cells, monocytes, neutrophils, and NK cells. In particular, recent data provided evidence that the accumulation of CD8+ T cells in the brains of infected animals and their production of granulysine B and perforin are required for the development of ECM (15, 18, 19). In 2013, Howell et al. (20) provided evidence that parasite-specific CD8+ T cells interact with parasite antigens cross-presented on major histocompatibility complex (MHC) class I molecules on the brain endothelium in ECM. Recently, Pai et al. (21) used two-photon intravital microscopy to visualize leukocyte behavior in the brains of PbA-infected mice during ECM. They showed that monocytes accumulated in the brain 1 or 2 days prior to the onset of neurological symptoms and showed decreased rolling speeds due to activation of the endothelium as disease severity increased. Adoptive transfer experiments showed that the behavior of monocytes was dependent on the recruitment of CD8+ T cells to the brain. Proinflammatory cytokines also appear to play a critical role in ECM, particularly gamma interferon (IFN-γ), tumor necrosis factor (TNF), and lymphotoxin α (7). Indeed, it was possible to induce ECM in ECM-resistant BALB/c mice by inducing proinflammatory cytokines by treatment with the Toll-like receptor agonist, CpG, during PbA infections (22). Taken together, these results support a model for the pathogenesis of ECM in which infection induces inflammatory cytokines that activate endothelial cells to process and present antigens from iRBCs that accumulated on the activated brain endothelium via MHC class I molecules, marking these cells as targets of parasite-specific CD8+ T cells (23).

The evolutionarily conserved serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating the outcome of antigen recognition in the adaptive immune system (24). mTOR functions at a central node of several evolutionarily conserved pathways that regulate stress responses, metabolism, apoptosis, and survival. By integrating these pathways with immune cell receptor signaling pathways, mTOR serves to regulate immune responses (25). Targeting mTOR by rapamycin is proving to be an effective means of suppressing immune responses primarily due to the ability of rapamycin to inhibit effector T cell differentiation and promote regulatory T cell (Treg) differentiation (25). In addition, rapamycin has been shown to inhibit parasite growth in vitro through its interaction with the single Plasmodium falciparum FK506 binding protein PFKBP35, and consequently, PFKBP35 is considered a promising target for antimalarial drugs (reviewed in reference 26). Although Plasmodium parasite genes do not encode an mTOR homolog, the mTOR ATP-competitive kinase inhibitors, Torins, have been recently shown to inhibit parasite growth (27), possibly through their inhibition of parasite phosphoinositide 3 kinases that are members of the mTOR family.

Here we provide evidence that rapamycin treatment administered as late as 4 days p.i. protects mice from ECM. The most striking effect of rapamycin on disease progression was the prevention of the breakdown of the BBB and brain hemorrhaging and the reduction in the numbers of T cells and iRBCs that accumulate in the brain. Rapamycin markedly altered transcriptional profiles in the brains of infected mice, and analysis of these transcriptional changes predicted that rapamycin inhibited leukocyte trafficking to and proliferation in the brain. Remarkably, rapamycin treatment is protective against ECM, despite significantly increasing immune inflammation both peripherally and in the brain. Rapamycin’s effect on parasite growth is complex in vivo, functioning to elevate peripheral parasitemia and decrease parasite loads in the brain. Recent studies suggest that several additional metabolic pathways that are activated in T cells following antigen recognition are also required to direct the resulting response (25). The results presented here open a new avenue for the development of adjunctive therapies for HCM by targeting metabolic pathways that regulate immune responses and possibly parasite growth.

RESULTS

Rapamycin treatment protects against ECM. To determine the effect of rapamycin on the development of ECM, C57BL/6 mice were infected with PbA and injected intraperitoneally with a vehicle control solution or with rapamycin (1.0 mg/kg of body weight) daily starting 1, 4, or 5 days p.i. All vehicle-treated mice developed severe neurological symptoms by day 6 p.i. and either died or were euthanized by day 9 p.i. (Fig. 1A). In contrast, mice that began daily rapamycin treatment on either day 1 or 4 p.i. did not develop symptoms of ECM and survived longer than untreated mice. Be-
In contrast, age of EB into the brain by visual inspection of the brains (Fig. 2A). The mice were monitored daily and scored for clinical neurological symptoms, and hemoglobin levels and parasitemias in peripheral blood were measured. (A) Percentage of mice in each group that survived with time after infection. (B) Hemoglobin levels measured in peripheral blood are given with time after infection. (C) The percentage of mice in each group that developed ECM defined as a clinical score above 6 with a hemoglobin level above 6 g/dl. (D) Peripheral blood parasitemias are given with time after infection. The results from one experiment representative of three independent experiments are shown. In two of the experiments, each experimental group had 8 to 10 mice; in the third experiment, each group had 5 mice. The parasitemia of mice treated with rapamycin (Rapa Rx) on day 1 was significantly higher than those of mice treated with Rapa Rx on day 4 or 5 and of control mice (no Rx) on 9 days p.i. Values that are statistically significantly different (P ≤ 0.0002) are indicated by the bracket and three asterisks.

FIG 1 Treatment of mice with rapamycin prevents experimental cerebral malaria (ECM). Mice were infected with Plasmodium berghei ANKA (PbA) by intraperitoneal injection of infected red blood cells (iRBCs) and treated with rapamycin (Rapa Rx) (1.0 mg/kg) or a control solution (no Rx) beginning on day 1 (d1), 4 (d4), or 5 (d5) postinfection (p.i.). The mice were monitored daily and scored for clinical neurological symptoms, and hemoglobin levels and parasitemias in peripheral blood were measured. (A) Percentage of mice in each group that survived with time after infection. (B) Hemoglobin levels measured in peripheral blood are given with time after infection. (C) The percentage of mice in each group that developed ECM defined as a clinical score above 6 with a hemoglobin level above 6 g/dl. (D) Peripheral blood parasitemias are given with time after infection. The results from one experiment representative of three independent experiments are shown. In two of the experiments, each experimental group had 8 to 10 mice; in the third experiment, each group had 5 mice. The parasitemia of mice treated with rapamycin (Rapa Rx) on day 1 was significantly higher than those of mice treated with Rapa Rx on day 4 or 5 and of control mice (no Rx) on 9 days p.i. Values that are statistically significantly different (P ≤ 0.0002) are indicated by the bracket and three asterisks.
mice treated daily with rapamycin beginning on day 4 p.i. compared to PbA-infected, untreated mice despite equivalent levels of peripheral parasitemia in rapamycin-treated compared to untreated PbA-infected mice (Fig. 1D). As expected, no qPCR amplification was detected in the brains of uninfected control mice with the same 18S ribosomal primers (data not shown). Taken together, these results show that administration of rapamycin as late as day 4 p.i. prevents the brain pathology associated with ECM, including breakdown of the BBB, brain hemorrhaging, and accumulation of iRBCs in the brain.

**Rapamycin results in increased production of proinflammatory cytokines and chemokines.** Because ECM is accompanied by the production of proinflammatory cytokines and chemokines, we determined the effects of rapamycin treatment on the serum levels of several inflammatory cytokines and chemokines, including interleukin 6 (IL-6), IL-10, IL-12p70, macrophage inflammatory protein 1α (MIP-1α), macrophage chemotactic attractant 1 (MCP-1), RANTES (regulated on activation, normal T cell expressed and secreted), IFN-γ, TNF-α, chemokine (C-X-C motif) ligand 1 (CXCL1), thymus and activation-regulated chemokine (TARC), and T cell alpha chemokine (TCA) using a cytokine array. Mice were uninfected or infected with PbA and left untreated or treated with rapamycin daily beginning on day 1 or 4 p.i. All mice were sacrificed on day 6 p.i., and sera were collected. The sera of PbA-infected, untreated mice had elevated levels of the proinflammatory molecules TCA, MIP-1α, CXCL1, MCP-1, RANTES, and IL-6 compared to uninfected mice, either treated with rapamycin or not treated with rapamycin (Fig. 3). The levels of IL-10, an anti-inflammatory cytokine often produced in response to inflammation (33), was also increased in PbA-infected, untreated mice as compared to uninfected controls. Remarkably, daily rapamycin treatment of PbA-infected mice beginning on day 4 p.i. resulted in significant increases in the serum levels of TCA, IFN-γ, MIP-1α, CXCL1, MCP-1, RANTES, and IL-6 (Fig. 3) compared to those of PbA-infected, untreated controls. The level of the anti-inflammatory cytokine IL-10, which was higher in PbA-infected mice than in uninfected mice, remained elevated in infected mice treated with rapamycin. In mice in which daily rapamycin treatment was started on day 1 p.i., we observed significantly higher levels of CXCL1 and significantly reduced levels of IL-10 (see Fig. S1 in the supplemental material) relative to PbA-infected, untreated controls. These findings provide evidence that rapamycin prevents ECM even though treatment augmented the PbA-induced systemic proinflammatory response.

**Rapamycin treatment reduced the accumulation of leukocytes in the brain.** ECM is accompanied by leukocyte sequestra-
The gating strategy used to identify total CD4+ perfused with phosphate-buffered saline (PBS). The brains and mice were terminally anesthetized on day 6 p.i. and transcardially or treated with rapamycin daily beginning on day 1, 4, or 5 p.i. All untreated (−) or treated with rapamycin (+) daily beginning on day 4 p.i. The levels of the following cytokines or chemokines are shown: TCA, IFN-γ, MIP-1α, CXCL1, IL-10, MCP-1, RANTES, and IL-6. Each experimental group contained 12 to 14 mice. The results from one experiment are shown. Values that are significantly different by Mann-Whitney tests are indicated by bars and asterisks as follows: *, P < 0.05; **, P < 0.005; ***, P < 0.0005.

FIG 3 Daily treatment of PbA-infected mice with rapamycin beginning on day 4 p.i. resulted in elevated levels of inflammatory cytokines and chemokines. Cytokine and chemokine levels were measured using a Q-Plex array mouse cytokine kit on day 6 p.i. in sera from uninfected mice or PbA-infected mice left untreated (−) or treated with rapamycin (+) daily beginning on day 4 p.i. The levels of the following cytokines or chemokines are shown: TCA, IFN-γ, MIP-1α, CXCL1, IL-10, MCP-1, RANTES, and IL-6. Each experimental group contained 12 to 14 mice. The results from one experiment are shown. Values that are significantly different by Mann-Whitney tests are indicated by bars and asterisks as follows: *, P < 0.05; **, P < 0.005; ***, P < 0.0005.

Rapamycin treatment during PbA infection induced marked transcriptional changes in the brain and spleen. To obtain a global view of how rapamycin treatment prevented cerebral disease in PbA infections, we carried out DNA microarray analyses of transcription in the brain, including CD4+ and CD8+ T cells, monocytes, neutrophils, and NK cells. We determined the number of total CD4+ and CD8+ T cells and the number of CD44+ effector/memory T cells, neutrophils, and NK cells in the brains and spleens of uninfected mice and PbA-infected mice that were either untreated or treated with rapamycin daily beginning on day 1, 4, or 5 p.i. All mice were terminally anesthetized on day 6 p.i. and transcardially perfused with phosphate-buffered saline (PBS). The brains and spleens were removed, processed, and analyzed by flow cytometry. The gating strategy used to identify total CD4+ and CD8+ T cells and effector/memory T cells, neutrophils, and NK cells is shown (see Fig. S2 in the supplemental material). We observed a large accumulation of CD8+ T cells in the brains of PbA-infected mice (1.0 × 10^5 cells per brain) (Fig. 4A) and a somewhat smaller accumulation of CD4+ T cells (3.0 × 10^4 cells per brain) (Fig. 4B) compared to uninfected mice. More than 80% of the CD8+ T cells that accumulated in the brain were CD44+ effector/memory T cells (Fig. 4C), and similarly, the majority of CD4+ T cells that accumulated in the brain, more than 60%, were CD44+ effector/memory T cells (Fig. 4D). Treatment of PbA-infected mice with rapamycin beginning on day 1 p.i. resulted in a dramatic reduction in the accumulation of both CD4+ T cells (an 88% reduction) and CD8+ T cells (a 99% reduction) in the brain (Fig. 4A to D). Treatment with rapamycin beginning on day 4 p.i. also resulted in reduced numbers of CD4+ and CD8+ T cells in the brain, and although these reductions were not as great as those observed in mice treated with rapamycin daily beginning on day 1 p.i., mice treated on day 1 or day 4 p.i. were similarly protected from ECM (Fig. 1C). There were no significant differences in the numbers of CD4+ or CD8+ T cells in the brains of mice treated with rapamycin on day 5 p.i. compared to untreated PbA-infected mice (Fig. 4A to D), which is consistent with the weak protection from ECM (20%) of mice treated with rapamycin on day 5 p.i. The effects of rapamycin on the expansion of CD8+ and CD4+ T cells in spleens were more modest than the effect on the accumulation of these cells in brains. The number of CD8+ effector/memory T cells increased approximately 3-fold in the spleens of PbA-infected mice as compared to uninfected mice. Rapamycin treatment inhibited this increase, with the most effective inhibition (67%) observed for mice treated with rapamycin beginning on day 1 p.i. (Fig. 4E). The number of CD4+ effector/memory T cells increased approximately 2-fold in the spleens of PbA-infected mice compared to uninfected mice, and rapamycin blocked this increase but only when treatment began on day 1 p.i. (Fig. 4F). Together these results suggest that rapamycin treatment functions to protect mice against ECM at least in part by blocking the expansion of effector/memory T cells in peripheral lymphoid tissues and their migration to the brain, resulting in greatly diminished numbers of T cells accumulating in the brains of infected mice. Compared to uninfected mice, the number of neutrophils dramatically increased (more than 100-fold) in the brains of PbA-infected mice, and rapamycin treatment beginning on day 1 or day 4 p.i. blocked this increase significantly. The number of neutrophils in the spleen did not increase with PbA infection, and rapamycin treatment resulted in increased numbers of neutrophils in the spleens of infected mice consistent with the ability of rapamycin to block neutrophil chemotaxis (34). The number of NK cells in the brains of PbA-infected mice increased 2.5-fold with PbA infection, but rapamycin treatment had no effect on this increase (data not shown).

Rapamycin treatment during PbA infection induced marked transcriptional changes in the brain and spleen. To obtain a global view of how rapamycin treatment prevented cerebral disease in PbA infections, we carried out DNA microarray analyses of
A. Brain CD8+ T cells

B. Brain CD4+ T cells

C. Brain effector/memory CD8+ T cells

D. Brain effector/memory CD4+ T cells

E. Spleen effector/memory CD8+ T cells

F. Spleen effector/memory CD4+ T cells

G. Brain Neutrophils

H. Spleen Neutrophils
both brains and spleens at day 6 p.i. in mice that were treated with rapamycin beginning on day 1 p.i. or left untreated. Thus, four experimental groups were analyzed: uninfected mice, uninfected mice treated with rapamycin daily beginning on day 1 p.i., PbA-infected mice, and PbA-infected mice treated with rapamycin daily beginning on day 1 p.i. For the brain, the olfactory bulb, right cerebrum, and cerebellum were analyzed separately. The number of differentially expressed genes (DEGs) (cutoff criteria, absolute fold change of >1.5 and a false discovery rate [FDR] of <5%) for all comparisons are shown in Table S1 in the supplemental material (four mice in each group). Compared to uninfected mice, PbA infection alone induced marked transcriptional changes in the olfactory bulb (1,107 DEGs), right cerebrum (509 DEGS), and cerebellum (589 DEGS). However, rapamycin treatment of PbA-infected mice also induced substantial changes compared to untreated PbA-infected mice, with 350 DEGs in the olfactory bulb, 215 DEGs in the right cerebrum, and 306 DEGs in the cerebellum. Notably, the vast majority of genes differentially expressed in PbA-infected mice treated with rapamycin compared to untreated mice overlapped with genes differentially expressed in PbA-infected versus uninfected mice (81% in the olfactory bulb, 78% in the right cerebrum, and 75% in the cerebellum) (Fig. 5A). Thus, rapamycin appears to abrogate cerebral disease in large part by altering the expression of the very same genes affected by PbA infection. An even greater number of DEGs was observed in PbA-infected spleens relative to uninfected spleens (2,560 DEGS) with a similarly high overlap between these DEGs and the 1,037 DEGs in rapamycin-treated, PbA-infected mice compared to untreated PbA-infected mice (see Fig. S3A in the supplemental material). It is important to note that rapamycin treatment of uninfected mice had little effect on the gene expression profiles relative to saline treatment (146 DEGs) and no effect on any part of the brains of uninfected mice (0 DEGs) (Table S1).

Differentially expressed gene sets from the PbA-infected, rapamycin-treated mice versus PbA-infected, untreated mice were further analyzed to determine which pathways were most highly affected by rapamycin treatment in the brain (Fig. 5B) and in the spleen (see Fig. S3B in the supplemental material). Canonical pathway enrichment analysis identified several affected pathways that were mutually overrepresented among the differentially expressed gene sets from all three brain tissues. These all involved immune cell pathways and included the following: granzyme A signaling; role of pattern recognition receptors; granulocyte/ agranulocyte adhesion, diapedesis, and activation of interferon regulatory factors by cytosolic pattern recognition receptors (Fig. 5B). The finding that the pathways most highly affected by rapamycin treatment were associated with immune cell function likely reflects the marked decrease observed in the numbers of immune cells, both T cells and neutrophils, in the brains of rapamycin-treated, PbA-infected mice relative to untreated, PbA-infected mice (Fig. 4A to D). In contrast, a number of immune pathways that are involved during PbA infection are not affected by rapamycin treatment, suggesting that certain PbA-affected pathways are distinct from the mechanism by which rapamycin blocks ECM. For example, expression of genes in the complement pathway are affected by PbA infection compared to uninfected mice in all three parts of the brain, but rapamycin treatment had no effect on this pathway (Fig. 5B). The expression of subunits comprising the C1q complement complex was increased upon infection (for C1qa, 1.7-fold change and an FDR of 0.98% in the cerebrum, 1.6-fold change and an FDR of 3.0% in the olfactory bulb, and 1.7-fold change and an FDR of 1.3% in the cerebellum; for C1qb, 1.9-fold change and an FDR of 0.0024% in the cerebrum, 2.2-fold change and an FDR of <0.0001% in the olfactory bulb, and 2.7-fold change and an FDR of <0.0001% in the cerebellum) and unchanged by rapamycin treatment (not significant for C1qa and C1qb in all tissues). Although increased expression of C1q in the brain (35) and periphery (35, 36) has been suggested to play a role in pathogenesis in ECM, our results suggest that the development of ECM can be blocked despite such increases. Intriguingly, the antigen presentation pathway, which was significantly affected by PbA infection in all three brain parts, was not altered in any case by rapamycin treatment (Fig. 5B). Consistent with this finding, expression of Tap1, which encodes an ATP-binding cassette peptide transporter that is critical in antigen processing for presentation on major histocompatibility class I molecules, was significantly upregulated in the brains of PbA-infected mice versus uninfected mice (3.8-fold change and an FDR of <0.0001% in the cerebrum, 4.0-fold change and an FDR of <0.0001% in the olfactory bulb, and 3.6-fold change and an FDR of <0.0001% in the cerebellum), strongly implying increased antigen presentation in PbA-infected mice. However, rapamycin treatment had no effect on these changes in Tap1 expression. This finding suggests that although PbA infection profoundly increases antigen presentation in the brain during infection, rapamycin-mediated protection against cerebral disease may not require the restoration of antigen presentation to uninfected levels.

**Genes discordantly regulated in PbA-infected mice treated with rapamycin are predicted to inhibit leukocyte recruitment and proliferation in brain tissue.** Significant overlap among the DEGs in the PbA-infected mice versus uninfected mice and the DEGs in the PbA-infected, untreated mice versus PbA-infected, rapamycin-treated mice suggests that rapamycin treatment may dampen specific subsets of genes that are induced by infection or vice versa. To identify changes in PbA-induced gene expression that were abrogated or reversed by rapamycin treatment, DEGs for each part of the brain and spleen were filtered on those genes that showed a >1.5-fold change in expression in the comparison of PbA-infected versus uninfected mice and a <−1.5-fold change in expression in the comparison of PbA-infected, rapamycin-
treated versus *PbA*-infected, untreated mice (or vice versa) using an FDR of <5% for each comparison as the threshold for significance. Figure 6A shows the expression intensities of the discordantly regulated genes in the right cerebrum for uninfected mice, *PbA*-infected mice, and *PbA*-infected, rapamycin-treated mice. Pathway enrichment analysis was applied to this filtered set of discordantly regulated genes to predict the regulator effect networks that are reversed or abrogated by rapamycin treatment during *PbA* infection (Fig. 6B). This network analysis predicted inhibition of the following immunological functions with rapamycin treatment during *PbA* infection: cellular invasion, cellular chemotaxis, lymphocyte proliferation, and chronic inflammation.

**FIG 5** Rapamycin treatment induces changes in granzyme signaling and cellular adhesion and diapedesis pathways in the brains of *PbA*-infected mice as determined by genome-wide DNA microarray analysis. Mice were infected with *PbA* or mock infected with saline and treated with either saline or rapamycin beginning on day 1 p.i. On day 6 p.i., all mice were anesthetized and perfused with ice-cold PBS, and RNA was isolated for transcriptional profiling by DNA microarray from three regions of the brain: olfactory bulb, right cerebrum, and cerebellum (four mice in each tissue for each condition). Differentially expressed genes (DEGs) with an absolute fold change of >1.5 (false discovery rate of <5%) were determined for the indicated comparisons by three-way repeated measures ANOVA. (A) Venn diagrams show the numbers of mutually exclusive and intersecting genes for each indicated comparison within each brain tissue type. (B) IPA canonical pathway enrichment analysis of the DEGs was used to compare the effect of *PbA* infection alone (left column in each column pair) with the effect of rapamycin on *PbA* infection (right column) for each brain tissue type. Columns were sorted by descending −log10 *P* value in the right column followed by the left column so that the most significantly enriched pathways are on top. Nonsignificant pathways (*P* ≥ 0.05 by Fisher’s exact test) are shown as white boxes. IRF, interferon regulatory factor; PKR, protein kinase R; NFAT, nuclear factor of activated T cells; JAK, Janus kinase; iCOS, inducible costimulator; iCOSL, iCOS ligand; NO, nitric oxide.

**FIG 6** Rapamycin treatment reverses *PbA* infection-induced transcriptional changes of genes involved in cellular chemotaxis, cellular invasion, and lymphocyte proliferation in the brains of *PbA*-infected mice. (A) Heatmaps demonstrate differently expressed genes identified by genome-wide DNA microarray analysis that have a change in expression of more than twofold for *PbA*-infected mice relative to uninfected mice and a change of less than minus twofold for *PbA*-infected, rapamycin-treated mice relative to untreated, *PbA*-infected mice or vice versa, using a false discovery rate of <5% (three-way repeated measures ANOVA) for each comparison as the threshold for significance. Rows represent samples from each of the four individual mice. (B) Discordantly regulated genes determined using a less stringent fold change criteria (change in expression of greater than 1.5-fold for *PbA*-infected relative to uninfected mice and a change of less than −1.5-fold for *PbA*-infected, rapamycin-treated mice relative to untreated, *PbA*-infected mice or vice versa) were applied to Ingenuity Pathway Analysis (IPA) to determine the top regulator effect network in the right cerebrum. Top-tier molecules indicate predicted upstream regulators of downstream molecules. Middle-tier molecules are genes from the data set that are discordantly regulated with rapamycin treatment in *PbA*-infected mice. Here, all genes were experimentally determined to be downregulated with rapamycin treatment. Bottom-tier “gears” denote predicted functions. Arrows denote activation pathways, whereas T-capped lines denote inhibitory pathways. Predicted inhibition (blue), predicted activation (orange), findings inconsistent with the state of the downstream molecule (yellow), and regulation that cannot be predicted (gray) are indicated.
(Fig. 6B). Thus, rapamycin treatment is predicted to reverse the effect of $PbA$ infection by altering critical immune cell pathways, including trafficking to the brain, proliferation in the brain, and cerebral inflammation. A similar analysis of discordantly regulated genes predicted chronic inflammation to be inhibited in the olfactory bulb with rapamycin treatment. However, no other immunological functions were found among the top regulator effect networks in the cerebellum using the same analysis of discordantly regulated genes.

There are several genes of interest in the set of discordantly regulated genes (Fig. 6A) that provide insights into the mechanisms underlying rapamycin’s effects. Expression of heme oxygenase 1 (HO-1; encoded by Hmox1) has been shown to be highly upregulated in $PbA$-infected, ECM-resistant mouse strains and to be required for protection against ECM (37). Unexpectedly, Hmox1 was among the discordantly regulated genes, demonstrating increased expression in $PbA$-infected mice relative to uninfected mice (2.8-fold change and an FDR of 0.008% in the cerebrum; 6.9-fold change and an FDR of < 0.0001% in the olfactory bulb) but decreased expression (−2.0-fold change and an FDR of 2.7% in the cerebrum; −2.3-fold change and an FDR of 0.27% in the olfactory bulb) in rapamycin-treated, $PbA$-infected mice (Fig. 6A). This finding suggests that Hmox1 may not be absolutely required for protection from ECM. CD8$^+$ T cells expressing granzyme B (encoded by Gzmb) have been demonstrated to be required for the development of ECM (15). Consistent with this, Gzmb expression significantly increased in the brains of $PbA$-infected mice exhibiting signs of ECM (in the right cerebrum, 5.7-fold change and an FDR of < 0.0001%; in the cerebellum, 6.2-fold change and an FDR of < 0.001%; in the olfactory bulb, 4.9-fold change and an FDR of < 0.0001%), but it significantly decreased in ECM-protected, $PbA$-infected mice treated with rapamycin at day 1 p.i. (in the right cerebrum, −2.8-fold change and an FDR of < 0.0001%; in the cerebellum, −2.5-fold change and an FDR of 0.0001%; in the olfactory bulb, −1.8-fold change and an FDR of 0.077%), a result that could be explained in part by decreased CD8$^+$ T cell recruitment in the brain (Fig. 4A and C).

An upstream regulator analysis of differentially expressed genes was carried out for all comparisons ($PbA$-infected mice versus uninfected mice and $PbA$-infected, rapamycin-treated mice versus $PbA$-infected mice). The results predicted genes involved in both type I and type II interferon responses (Ifng, Irf7, Ifna2, Irf3, Stat1, and Ifnb1) and proinflammatory genes (Tnf, Il1b, and Il6) as transcriptional activators in $PbA$-infected mice relative to uninfected controls both in the brain (Fig. 7A to C) and in the spleen (see Fig. S3C in the supplemental material). Consistent with the results of the serum cytokine analyses (Fig. 3 and Fig. S1), treatment of $PbA$-infected mice with rapamycin further increased activation of both interferon and proinflammatory pathways in the spleen (Fig. S3C). Notably, treatment of $PbA$-infected mice with rapamycin increased activation of interferon response genes in the brain (Irf7, Irf3, Ifna2, Ifnb1, and Ifng), but not proinflammatory genes downstream of the interferons (Tnf, Il1b, and Il6) (defined as a Z score of ≥ 2 and $P < 0.01$) (Fig. 7A to C). This suggests that, in the brain, rapamycin-mediated augmentation of inflammatory responses during $PbA$ infection may be limited to the innate, interferon-related response and truncated prior to the initiation of the downstream mediators of inflammation. In contrast, rapamycin-mediated augmentation of the inflammatory response in the spleen during $PbA$ infection involves both innate interferon-related responses as well as downstream mediators of inflammation.

**Treatment with rapamycin increased parasitemia by modulating the adaptive immune response.** The results presented thus far provide strong evidence that rapamycin treatment daily beginning on day 1 p.i. or as late as day 4 p.i. protects mice from the pathology of ECM. However, rapamycin treatment beginning at day 1 p.i. also resulted in an increase in peripheral parasitemia compared to untreated $PbA$-infected mice (Fig. 1D), resulting in a drop in hemoglobin levels (Fig. 1B). The effect of rapamycin treatment on parasitemia appeared to be specific for the ECM-causing $PbA$, as rapamycin treatment of mice infected with the closely related parasite $PbNK65$ did not result in a rise in peripheral parasitemia (Fig. 8A). Rapamycin treatment had some effects on parasitemia in $PbNK65$-infected mice, but the effects were small. Rapamycin treatment appeared to delay the rise in $PbNK65$ parasitemia compared to untreated mice (Fig. 8A), perhaps consistent with the reported inhibitory effect of rapamycin on parasite growth in vitro (26). Rapamycin treatment resulted in hemoglobin levels that dropped somewhat more slowly during the course of infection in $PbNK65$-infected, rapamycin-treated mice compared to untreated infected mice (Fig. 8B), and the rapamycin-treated mice survived longer (Fig. 8C). To determine whether rapamycin’s effect on parasitemia was intrinsic to $PbA$ or was dependent on the host’s immune response, recombination-activating gene product 1 (RAG-1)−deficient mice (RAG-1 [KO] [knockout]) that lack B and T cells were infected with $PbA$ and treated with rapamycin or a saline control. $PbA$ infection does not cause ECM in RAG-1 [KO] mice, because the functions of CD8$^+$ and CD4$^+$ T cells are required for ECM pathology. Thus, $PbA$-infected RAG-1 [KO] mice survive longer than $PbA$-infected C57BL/6 mice and ultimately die of severe anemia caused by hyperparasitemia. Rapamycin treatment did not cause an increase in parasitemia in RAG-1 [KO] mice compared to untreated, $PbA$-infected RAG-1 [KO] mice (Fig. 8D), resulting in similar decreases in hemoglobin levels and survival in treated and untreated mice (Fig. 8E and F). Thus, rapamycin’s effect on $PbA$ parasitemia does not appear to be due to a direct effect on $PbA$ growth in vivo but rather to an indirect effect on adaptive-immune-response-dependent mechanisms that control parasitemia.

For rapamycin treatment to be useful as an adjunctive therapy, it will be necessary to control the rapamycin-induced increase in parasitemia. To determine the feasibility of increasing survival following rapamycin treatment with antimalarials, $PbA$-infected mice treated with rapamycin beginning on day 1 or day 4 p.i. were treated with three daily doses of artesunate beginning on day 7 p.i. when parasitemias rise rapidly in rapamycin-treated, $PbA$-infected mice. Artesunate treatment reduced parasitemias, increased hemoglobin levels, and increased survival of $PbA$-infected, rapamycin-treated mice compared to mice not given artesunate (Fig. 9A to C). Treatment of $PbA$-infected mice with artesunate alone on day 7 p.i. was not feasible, as nearly all mice die by day 7 p.i. in the absence of rapamycin treatment. Thus, rapamycin treatment in conjunction with artesunate treatment results in a significant increase in survival of $PbA$-infected mice.

**DISCUSSION**

HCM, a common form of severe malaria, imposes a heavy health burden in sub-Saharan Africa in childhood mortality and among survivors in long-term neurological deficits. At present, we have
no adjunctive therapies for HCM, and the development of such therapies would benefit greatly from a clearer understanding of the parasite and host mechanisms that underlie the pathology of HCM. Although our understanding of such mechanisms is far from complete, it seems likely that HCM pathology may have multiple causes with contributions from both the parasite and the host, particularly the host’s immune response. HCM and ECM in mice share a number of features, including sequestration of iRBCs in the brain microvasculature, breakdown of the BBB, and elevated levels of proinflammatory cytokines (7, 13). It is well established that in ECM, CD8$^+$ T cells play a critical role in the pathogenesis of the infection (13), whereas in HCM, the functions of leukocytes observed in the brain vasculature (5, 12) remain uncharacterized.

Here we explored the effect of the mTOR inhibitor rapamycin on the progression of ECM in mice. Figure 10 depicts our current model for the effect of rapamycin on ECM. Rapamycin is an attractive candidate for therapy, as it has proven to be an effective means of suppressing immune responses (25). Moreover, rapamycin has been shown to inhibit the growth of $P. falciparum$ in vitro through its binding to the parasite homolog of the mammalian FK506 binding protein (26). The effectiveness of rapamycin as an immunosuppressant is likely due to its ability to inhibit effector T cell differentiation and to inhibit effector T cell metabolism and thus function (25). Rapamycin treatment of mice during the first 3 days of infection was recently shown to increase survival in ECM with a concomitant decrease in the accumulation of CD8$^+$ and CD4$^+$ T cells in the brain (38). We observed that treatment with rapamycin as late as day 4 p.i. prevented ECM in mice. Treated mice showed none of the signs of pathology of ECM, including

no adjunctive therapies for HCM, and the development of such therapies would benefit greatly from a clearer understanding of the parasite and host mechanisms that underlie the pathology of HCM. Although our understanding of such mechanisms is far from complete, it seems likely that HCM pathology may have multiple causes with contributions from both the parasite and the host, particularly the host’s immune response. HCM and ECM in mice share a number of features, including sequestration of iRBCs in the brain microvasculature, breakdown of the BBB, and elevated levels of proinflammatory cytokines (7, 13). It is well established that in ECM, CD8$^+$ T cells play a critical role in the pathogenesis of the infection (13), whereas in HCM, the functions of leukocytes observed in the brain vasculature (5, 12) remain uncharacterized.

Here we explored the effect of the mTOR inhibitor rapamycin on the progression of ECM in mice. Figure 10 depicts our current model for the effect of rapamycin on ECM. Rapamycin is an attractive candidate for therapy, as it has proven to be an effective means of suppressing immune responses (25). Moreover, rapamycin has been shown to inhibit the growth of $P. falciparum$ in vitro through its binding to the parasite homolog of the mammalian FK506 binding protein (26). The effectiveness of rapamycin as an immunosuppressant is likely due to its ability to inhibit effector T cell differentiation and to inhibit effector T cell metabolism and thus function (25). Rapamycin treatment of mice during the first 3 days of infection was recently shown to increase survival in ECM with a concomitant decrease in the accumulation of CD8$^+$ and CD4$^+$ T cells in the brain (38). We observed that treatment with rapamycin as late as day 4 p.i. prevented ECM in mice. Treated mice showed none of the signs of pathology of ECM, including

FIG 7 Upstream regulator analysis reveals tissue-specific augmentation of interferon responses in $PbA$-infected mice treated with rapamycin. (A to C) Differentially expressed genes with an absolute fold change of $>1.5$ (false discovery rate of $<5\%$ by three-way repeated measures ANOVA) for each 2-way comparison were applied to IPA upstream regulator analysis to compare the effect of $PbA$ infection alone (left column in each column pair) and the effect of rapamycin on $PbA$ infection (right column) on predicted upstream transcriptional regulators in the olfactory bulb (A), right cerebrum (B), and cerebellum (C). Heatmaps demonstrate activation Z scores for predicted upstream activators (increasing red intensity) or predicted upstream inhibitors (increasing blue intensity) (overlap $P$ value of $<0.01$ by Fisher’s exact test). Column pairs are sorted by descending absolute Z scores on either the first comparison (left columns) or the second comparison (right columns). Only Z scores of less than $-2$ or more than 2 are considered significant. Therefore, a $|Z$ score$|$ of $<2$ is denoted by one asterisk for the first column and by two asterisks for the second column for each column pair.
breakdown of the BBB, brain hemorrhaging, and neurological symptoms. Treatment with rapamycin resulted in a dramatic decrease in the number of CD8^+ T cells that accumulated in the brains of infected mice as well as the number of iRBCs in the brain vasculature. CD8^+ T cells have been established to play a critical role in ECM (13). Recent studies provided evidence that CD8^+ T cells engage parasite-derived peptides presented on MHC class I molecules on brain endothelium and in a perforin-dependent process damage the endothelium (20). On the basis of these observations, we propose that rapamycin blocks the differentiation of CD8^+ effector T cells in lymphoid organs and their migration to the brain, and in the absence of CD8^+ effector T cells in the brain, ECM does not develop.

Our comparison of the gene transcription profiles of unin-
Infected mice, PbA-infected mice, and PbA-infected, rapamycin-treated mice provided several novel insights into the molecular and cellular mechanisms underlying ECM. Perhaps most informative was the analysis of genes that were discordantly regulated in the brain; that is genes that were expressed at higher levels in PbA-infected mice compared to uninfected mice but at lower levels in PbA-infected, rapamycin-treated mice compared to untreated mice or vice versa. Analysis of the discordantly regulated genes showed that many such genes in the right cerebrum were involved in networks that regulate cellular chemotaxis and invasion and the proliferation of lymphocytes. Notably, PbA-induced upregulation of Gzmb, which encodes granzyme B and plays an essential role in the development of ECM during PbA infection in C57BL/6 mice (15), was significantly reversed with rapamycin treatment. These findings provide further evidence linking the recruitment of CD8⁺ effector T cells to the brain with neuropathology, which may occur from endothelial damage by CD8⁺ T cell-mediated cytotoxicity.

Remarkably, rapamycin treatment protected the brains of PbA-infected mice despite inducing significant increases in inflammation both peripherally and in the brain. This conclusion was supported by our analyses of both cytokines and chemokines in peripheral blood and changes in gene transcription in the spleen and in the brain. The analyses of cytokines in serum provided evidence for large increases in inflammatory cytokines and a decrease in the anti-inflammatory cytokine IL-10. Comparisons of changes in gene transcription in the brains of PbA-infected mice compared to uninfected mice and in PbA-infected, rapamycin-treated mice showed that several inflammatory pathways were upregulated upon infection but even further upregulated upon rapamycin treatment. These findings were unexpected, since many studies have implicated inflammation as an integral aspect of CM pathogenesis. In fact, many features of severe malaria have been considered to be similar to those of sepsis (39), a condition of overwhelming inflammation. Intriguingly, our transcription analysis predicted that among the inflammatory genes,
only genes related to the interferon response would be activated in the brains of rapamycin-treated, PbA-infected mice. Although downstream mediators of inflammation such as Tnf, Il1b, and Il6 were predicted to be activated in the spleen after rapamycin treatment, similar activation of Tnf, Il1b, and Il6 was not observed at any of the brain sites. These results suggest that the inflammatory cascade in the brains of PbA-infected mice might be truncated or diminished locally by rapamycin treatment. In support of this, Hmox1, which is induced in response to oxidative stress and protects against ECM (37), was unexpectedly downregulated in the brains, but not the spleens, of PbA-infected mice treated with rapamycin, suggesting that rapamycin protects from ECM by limiting oxidative stress events proximal to the induction of Hmox1. One could speculate that decreased recruitment of leukocytes to the brain conferred by rapamycin treatment reduces cytotoxic CD8+ T cell-mediated end-organ damage and therefore limits inflammation and oxidative stress locally. Thus, limited end-organ inflammation could provide a possible explanation for why ECM was not observed in rapamycin-treated mice despite increased systemic inflammation. However, it remains to be seen whether this is a direct effect of rapamycin or simply a consequence of decreased leukocyte recruitment to the brain during PbA infection. Rapamycin treatment may uncouple the PbA-induced host inflammatory response, which may not in itself be necessary for the development of ECM, from the CD8+ T cell-mediated response, which is required for ECM pathogenesis.

The results presented here also show that rapamycin treatment protects against ECM despite significantly increasing peripheral parasitemia. However, of perhaps greater importance, rapamycin treatment reduced parasite sequestration in the brains of infected mice which may be critical to ECM pathogenesis. In children with severe malaria, total parasite biomass, quantified by the serum concentration of *P. falciparum* histidine-rich protein 2 (*P*HRP2), was shown to be higher in fatal cases than in nonfatal cases despite both groups having equivalent peripheral parasitemias (40). Using the plasma concentrations of *P*HRP2 to quantify total, circulating, and sequestered parasite biomass, Cunnington et al. (41) recently showed that the sequestered biomass tended to be higher in children with HCM than in children with uncomplicated malaria, suggesting that sequestration of parasites in the brain, not total body parasitemia, may be critical to HCM pathogenesis (11). The mechanism by which rapamycin treatment enhanced parasite growth is also of potential interest. The observation that rapamycin treatment had no effect on parasite growth in RAG [KO] mice lacking an adaptive immune system suggests that rapamycin does not act directly on parasites but rather functions to relieve an immune mechanism that normally controls parasite growth. Understanding the nature of this mechanism may provide new targets for antimalarial drugs.

The demonstration that inhibiting mTOR-controlled metabolic pathways by treatment with rapamycin prevented the development of ECM opens up a new avenue toward developing adjunctive therapies for HCM by targeting the metabolism of the host immune cells. Recent studies suggest that several additional metabolic pathways are activated in T cells upon antigen recognition and are required for directing the resulting response (reviewed in reference 25). These pathways involve the transcription factors MYC, which drives cell growth and apoptosis and regulates glycolytic metabolism, and H11P, which regulates metabolism under hypoxic conditions as well as the serine/threonine kinase 5' AMP-activated protein kinase (AMPK), which senses AMP/ATP ratios in cells to regulate cellular functions. Each of these pathways has critical and selective roles in defining T cell function and fate. Depending on the immune mechanisms at play in CM, inhibitors of these pathways may be more effective than rapamycin in controlling disease. For example, treatment with rapamycin inhibits the generation of effector CD8+ T cells, requiring that rapamycin be administered before day 5 p.i., a time when the clinical symptoms of ECM are generally not apparent. It may be that inhibitors of metabolic pathways that are required for continued effector functions of T cells already present in the brains during CM could be delivered much later when neurological symptoms appear. Although best studied in T cells, metabolic pathways controlled by mTOR regulate diverse immune cell types that may play roles in HCM, including B cells, NK cells, neutrophils, and mast cells. Searches for inhibitors of cellular metabolism that block critical late immune cell function in CM may provide highly effective adjunctive therapies for HCM.

**MATERIALS AND METHODS**

**Ethics statement.** All experiments were approved by the National Institute of Allergy and Infectious Diseases Animal Care and Use Committee.

**Animals and malaria infections.** C57BL/6 and C57BL/6- [KO] RAG-1 female mice (7 to 10 weeks old) were obtained from the Jackson Laboratory. Mice were infected with either PbA or PbNK65 (New York line) by injecting 1 × 10^8 PbA- or PbNK65-IRBCs obtained from infected C57BL/6 mice intraperitoneally (i.p.). Hemoglobin levels in blood samples taken from the tail vein (<10 μl/day) were determined using a HemoCue HB201+ (HemoCue AB, Angelholm, Sweden). Peripheral parasitemia was determined in blood either by Wright-Giemsa-stained whole-blood smears or by flow cytometry as described below. Infected mice were monitored for the progression of experimental cerebral malaria (ECM) using a 10-point clinical scoring system that rates mice as symptomless (a score of 0), moribund (a score of 10), as previously described (42). According to our animal protocol, mice with a clinical score of 6 or greater and severely anemic mice with a hemoglobin level below 2.5 g/dl were euthanized.

**Rapamycin and artesunate treatment.** For rapamycin treatment, a stock solution of rapamycin (catalog no. R0395; Sigma Aldrich) was prepared by dissolving rapamycin in pure ethanol (25 mg/ml). For treatment of mice, which weighed approximately 20 g in these studies, the stock rapamycin solution was diluted in a solution of 5% polyethylene glycol 4000 (Sigma), 4% ethanol, and 5% Tween 80 for a final concentration of rapamycin of 1 mg/ml. Mice were injected intraperitoneally with 1 mg/kg rapamycin every day starting on day 1, 4, or 5 p.i., unless otherwise noted. For artesunate treatment, 60 mg of artesunate (catalog no. A3731; Sigma) was dissolved in 1 ml of 5% sodium bicarbonate, to which 4 ml of 5% dextrose was added for a final concentration of 12 mg/ml. One hundred milligrams per kilogram was administered i.p. to mice on the specified days.

**Flow cytometry of brain and spleen leukocytes.** Mice were anesthetized with ketamine/xylazine 6 days p.i. and transcardially perfused with ice-cold PBS, and the brains and spleens were removed. The brains were dissected, minced, and digested with 1 mg/ml collagenase D for 30 min at 37°C. After the tissue was passed through 70-μm nylon mesh, homogenates were placed on a 90%–60%–40% discontinuous Percoll gradient and centrifuged for 18 min at 1,000 × g, and the cells at the 40%–60% interface containing mostly leukocytes were collected for analysis. The spleens were minced and forced through a 70-μm nylon mesh, and the cell suspension was incubated for 10 min in a solution of ammonium-chloride-potassium (ACK; Lonza) to lyse RBCs. The cells were washed and resuspended in RPMI 1640 with 10% heat-inactivated fetal bovine serum (FBS). The cells from both brain and spleen were stained in fluorescence-activated cell sorting (FACS) buffer (PBS plus 1% FBS). The
following fluorescent-dye-conjugated antibodies specific for the following cell surface markers were used for staining: brilliant violet 421-conjugated NK1.1 (BV421–NK1.1) (BioLegend), BV605–CD4 (Bio-Legend), BV785–CD8 (BioLegend), phycoerythrin-conjugated Ly6G (PE–Ly6G) (BD Pharmingen), phycoerythrin-and-CD7-conjugated CD3 (PE–Cy7–CD3) (eBioscience), allopochyrysin-conjugated Ly6C (APC–Ly6C) (BD Pharmingen), Alexa Fluor 700-conjugated CD44 (AF700–CD44) (eBioscience), APC–Cy7–CD45.2 (BD Pharmingen), and LIVE/DEAD (Aqua; Invitrogen). Gating of subsets is depicted in Fig. S1 in the supplemental material. Cell acquisition data were obtained on a BD LSRII flow cytometer. Data were analyzed with FlowJo software (Tree Star Technologies).

Assessment of BBB integrity. Evans blue (20 mg/kg) was injected intravenously on day 6 p.i., and 3 h later, the mice were anesthetized and perfused, and the brains were removed and immediately frozen at −80°C for later processing. EB was quantified by a modified version of the previously described protocol (43). Briefly, EB was extracted from brains with one perfused brain per 2-ml skirted screw cap tube (Greiner). Seven hundred microliters of N,N-dimethylformamide (DMF) (catalog no. D4551; Sigma) was added with three silica beads (2.3 mm) (catalog no. 11079125; Biospec) per tube and homogenized for 1 min at room temperature (Minibeadbeater-16 model 607; BioSpec Products). This homogenized solution was centrifuged at 16,000 × g for 20 min at 4°C. The supernatant was transferred to a separate tube and spun again at the same speed and temperature for 10 min. Two hundred microliters of this supernatant was then quantified in duplicate using a Variskan Flash fluorometer (620-nm excitation; 695-nm emission; Thermo Scientific). For quantification, a standard curve was generated using a uninfected peripheral blood. The numbers of hemorrhages were counted and averaged.

Cytokine measurements. Blood samples were collected on day 6 p.i., and sera were stored at −80°C until analyzed for IL-6, IL-10, IL-12p70, MIP-1α, MCP-1, RANTES, IFN-γ, tumor necrosis factor alpha (TNF-α), IL-1β, CXCL1, TARC, and TCA using the Q-Plex array mouse cytokine kit (Quansys Biosciences) according to the manufacturer’s instructions.

Microarray chip processing and data analysis. C57BL/6 mice were infected with Plasmodium berghei or mock infected with saline vehicle and treated with either saline or rapamycin beginning on day 1 p.i. (4 conditions; 4 mice for each condition). On day 6 p.i., the mice were anesthetized and perfused with saline, and samples from 4 tissues (spleen, right cerebrum, cerebellum, and olfactory bulb; 64 samples total) were immediately frozen in liquid nitrogen. RNA was isolated. For each sample, labeled target was combined with 2× hybridization buffer, 3 mM B2 control oligonucleotide (catalog no. 900457; Affymetrix), 20× hybridization control stock (Affymetrix), and dimethyl sulfoxide (DMSO) making a final volume of 150 µl for the individual hybridizations to the Affymetrix GeneChip mouse gene 2.0 ST array containing the C57BL/6 mouse genome. The hybridization cocktial, including the components listed above, was denatured for 5 min at 99°C and then transferred to a 45°C heat block for an additional 5 min before transferring 130 µl of the cocktail onto the chip. The hybridization was carried out at a constant temperature of 45°C for approximately 40 h using an Affymetrix 640 hybridization oven. Upon completion of the hybridization step, each sample was removed from the chip and archived. Each chip was filled with approximately 160 µl of wash buffer A and then processed on the fluidics station 450. The reagents for the stain mixture consisted of 2× morpholineethanesulfonic acid (MES) stain buffer, 50 mg/ml of bovine serum albumin (BSA), 1 mg/ml of streptavidin phycoerythrin and water to make up a total volume of 600 µl for each stain. A holding buffer was added to make up a total volume of 800 µl for storage and scanning. Upon completion of the fluidics process, each sample was scanned using the Affymetrix GeneChip 3000 7Gplus scanner, and an expression console (Affymetrix version 1.3) was used to convert the data files to intensity (cel) files. The quality analysis was performed according to the “Quality Assessment of Exon and Gene Arrays” (Affymetrix revision 1.1). cel files representing individual samples were normalized using robust multiarray average (RMA) normalization followed by median normalization. Filtering was performed to remove any probe with mean log expression of all samples below 5.0 or log standard deviation of all samples below 1. Sample quality control was performed using principal component analysis (PCA) and sample-wise density plots in R. No outliers were identified in any of the aforementioned quality control methods used.

An empirical Bayes modified three-way repeated-measure analysis of variance (ANOVA) was computed between the different treatment conditions using the limma package library in R to obtain false discovery rate (FDR)-adjusted P-values and fold changes. The values for the probes were considered statistically significant if their FDR-adjusted P-values were <0.05 and their absolute fold change was >1.5 except where otherwise

Rapamycin Blocks Cerebral Malaria

May/June 2015 Volume 6 Issue 3 e00725-15
noted. Gene symbols, log fold change ratios, P values, and false discovery rates from the empirical Bayes ANOVA were imported into Ingenuity Pathway Analysis (IPA) (Qiagen) to determine pathway enrichment scores and perform upstream regulator and regulator effect analyses. Network diagrams were exported from IPA, and heatmaps were generated with the pheatmap package and ggplot libraries in R.

**Statistical analysis.** Statistical analyses of nonmicroarray data were computed using the latest versions of GraphPad Prism 6. Most comparisons are unpaired Mann-Whitney tests with Bonferroni’s adjustments for multiple comparisons applied when appropriate. Student’s t test was computed for the qPCR data to allow for easier fold change calculation. One-way ANOVA with Tukey posthoc adjustments for multiple comparisons was used for the log_{10}-transformed cell count data in Fig. 4. All survival curves are Kaplan-Meier curves with any log rank tests for any comparisons among curves.

**SUPPLEMENTAL MATERIAL**


Figure S1, PDF file, 1.6 MB.

Figure S2, PDF file, 1.1 MB.

Figure S3, PDF file, 2.2 MB.

Table S1, DOCX file, 0.01 MB.

**ACKNOWLEDGMENTS**

This study was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

**REFERENCES**


